◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › JNJ

Johnson & Johnson (JNJ) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-11

Johnson & Johnson (JNJ) operates in the Pharmaceuticals industry and is headquartered in New Brunswick, United States with about 138,200 employees. Its market capitalization is roughly $635 billion. In the fiscal year ended 2025-12-31, JNJ reported $94.2B in revenue and $26.8B in net income.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Interactive charts & full statements → Open the JNJ valuation workbench →

JNJ Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$96.4B	$94.2B	$88.8B	$85.2B	$80.0B	$78.7B	$82.6B	$82.1B	$81.6B	$76.5B	$71.9B	$70.1B	$74.3B	$71.3B	$67.2B	$65.0B	$61.6B	$61.9B	$63.7B	$61.1B	$53.3B
Gross Profit	$66.6B	$68.6B	$61.4B	$58.4B	$55.4B	$55.3B	$54.2B	$54.5B	$54.5B	$51.0B	$50.1B	$48.5B	$51.6B	$49.0B	$45.6B	$44.7B	$42.8B	$43.5B	$45.2B	$43.3B	$38.3B
Gross Margin %	69.1%	72.8%	69.1%	68.6%	69.2%	70.3%	65.6%	66.4%	66.8%	66.7%	69.7%	69.3%	69.4%	68.7%	67.8%	68.7%	69.5%	70.2%	71.0%	71.0%	71.8%
Operating Income (EBIT)	$25.9B	$25.6B	$22.1B	$21.9B	$21.0B	$20.9B	$19.7B	$21.0B	$21.2B	$18.9B	$20.9B	$18.3B	$21.1B	$19.0B	$17.0B	$16.2B	$16.5B	$16.7B	$16.2B	$15.2B	$13.7B
Operating Margin %	26.9%	27.2%	24.9%	25.7%	26.3%	26.6%	23.9%	25.6%	26.0%	24.7%	29.1%	26.1%	28.4%	26.6%	25.3%	24.8%	26.8%	26.9%	25.4%	24.9%	25.7%
Net Income	$21.0B	$26.8B	$14.1B	$35.2B	$17.9B	$20.9B	$14.7B	$15.1B	$15.3B	$1.3B	$16.5B	$15.4B	$16.3B	$13.8B	$10.9B	$9.7B	$13.3B	$12.3B	$12.9B	$10.6B	$11.1B
Net Margin %	21.8%	28.5%	15.8%	41.3%	22.4%	26.5%	17.8%	18.4%	18.8%	1.7%	23.0%	22.0%	22.0%	19.4%	16.1%	14.9%	21.6%	19.8%	20.3%	17.3%	20.7%
EBITDA	$33.5B	$41.1B	$24.8B	$29.3B	$26.6B	$26.8B	$23.9B	$24.7B	$25.9B	$24.2B	$24.3B	$23.5B	$25.0B	$20.1B	$18.0B	$16.1B	$20.3B	$19.0B	$20.2B	$16.4B	$15.9B
Earnings Per Share (EPS)	$8.65	$11.03	$5.79	$13.73	$6.73	$7.81	$5.51	$5.63	$5.61	$0.47	$5.93	$5.48	$5.70	$4.81	$3.86	$3.49	$4.78	$4.40	$4.57	$3.63	$3.73
Shares Outstanding (M)	2,445M	2,429M	2,429M	2,560M	2,664M	2,674M	2,671M	2,684M	2,729M	2,745M	2,789M	2,813M	2,864M	2,877M	2,813M	2,775M	2,789M	2,789M	2,836M	2,911M	2,963M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$24.1B	$24.6B	$24.0B	$23.7B	$21.9B	$22.5B	$22.5B	$22.4B
Gross Profit	$17.2B	$16.6B	$16.7B	$16.1B	$14.5B	$15.4B	$15.5B	$15.6B
Gross Margin %	71.5%	67.6%	69.6%	67.9%	66.4%	68.3%	69.0%	69.4%
Operating Income (EBIT)	$6.4B	$5.6B	$7.1B	$6.8B	$6.3B	$3.8B	$5.3B	$6.7B
Operating Margin %	26.6%	22.8%	29.6%	28.7%	28.8%	17.1%	23.5%	29.7%
Net Income	$5.2B	$5.1B	$5.2B	$5.5B	$11.0B	$3.4B	$2.7B	$4.7B
Net Margin %	21.8%	20.8%	21.5%	23.3%	50.2%	15.2%	12.0%	20.9%
EBITDA	$8.3B	$7.2B	$9.3B	$8.7B	$15.6B	$5.9B	$5.4B	$7.8B
Earnings Per Share (EPS)	$2.14	$2.10	$2.12	$2.29	$4.54	$1.41	$1.11	$1.93
Shares Outstanding (M)	2,445M	2,439M	2,429M	2,419M	2,424M	2,427M	2,428M	2,422M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$22.9B	$24.5B	$24.3B	$22.8B	$21.2B	$23.4B	$23.5B	$23.4B	$22.2B	$21.1B	$18.8B	$19.3B	$18.5B	$17.4B	$15.4B	$14.3B	$16.4B	$16.6B	$15.0B	$15.2B	$14.2B
Capital Expenditures (CapEx)	$5.1B	$4.8B	$4.4B	$4.5B	$4.0B	$3.7B	$3.3B	$3.5B	$3.7B	$3.3B	$3.2B	$3.5B	$3.7B	$3.6B	$2.9B	$2.9B	$2.4B	$2.4B	$3.1B	$3.3B	$2.7B
Free Cash Flow (FCF)	$17.8B	$19.7B	$19.8B	$18.2B	$17.2B	$19.8B	$20.2B	$19.9B	$18.5B	$17.8B	$15.5B	$15.8B	$14.8B	$13.8B	$12.5B	$11.4B	$14.0B	$14.2B	$11.9B	$11.9B	$11.5B
FCF Margin %	18.5%	20.9%	22.3%	21.4%	21.5%	25.1%	24.4%	24.3%	22.7%	23.2%	21.6%	22.6%	19.9%	19.4%	18.5%	17.5%	22.7%	22.9%	18.7%	19.5%	21.6%
Dividends Paid	$12.5B	$12.4B	$11.8B	$11.8B	$11.7B	$11.0B	$10.5B	$9.9B	$9.5B	$8.9B	$8.6B	$8.2B	$7.8B	$7.3B	$6.6B	$6.2B	$5.8B	$5.3B	$5.0B	$4.7B	$4.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$2.5B	$7.3B	$9.2B	$3.9B	$4.2B	$7.0B	$8.0B	$5.6B
Capital Expenditures (CapEx)	$1.0B	$1.8B	$788M	$1.4B	$795M	$2.1B	$2.3B	$976M
Free Cash Flow (FCF)	$1.5B	$5.5B	$8.4B	$2.5B	$3.4B	$4.8B	$5.7B	$4.7B
FCF Margin %	6.1%	22.3%	34.9%	10.4%	15.4%	21.5%	25.4%	20.8%
Dividends Paid	$3.1B	$3.1B	$3.1B	$3.1B	$3.0B	$3.0B	$3.0B	$3.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$200.9B	$199.2B	$180.1B	$167.6B	$187.4B	$182.0B	$174.9B	$157.7B	$153.0B	$157.3B	$141.2B	$133.4B	$130.4B	$132.7B	$121.3B	$113.6B	$102.9B	$94.7B	$84.9B	$81.0B	$70.6B
Cash & Cash Equivalents	$21.7B	$19.7B	$24.1B	$21.9B	$12.9B	$14.5B	$14.0B	$17.3B	$18.1B	$17.8B	$19.0B	$13.7B	$14.5B	$20.9B	$14.9B	$24.5B	$19.4B	$15.8B	$10.8B	$7.8B	$4.1B
Total Liabilities	$119.7B	$117.7B	$108.6B	$98.8B	$110.6B	$108.0B	$111.6B	$98.3B	$93.2B	$97.1B	$70.8B	$62.3B	$61.4B	$58.6B	$56.5B	$56.6B	$46.3B	$44.1B	$42.4B	$37.6B	$31.2B
Total Debt (Short + Long-Term)	$55.0B	$47.9B	$36.6B	$29.3B	$39.6B	$33.8B	$35.3B	$27.7B	$30.5B	$34.6B	$27.1B	$19.9B	$18.8B	$18.2B	$16.2B	$19.6B	$16.8B	$14.5B	$11.9B	$9.5B	$6.6B
Total Shareholders' Equity	$81.2B	$81.5B	$71.5B	$68.8B	$76.8B	$74.0B	$63.3B	$59.5B	$59.8B	$60.2B	$70.4B	$71.2B	$69.8B	$74.1B	$64.8B	$57.1B	$56.6B	$50.6B	$42.5B	$43.3B	$39.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JNJ viewer.

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.07 trillion
MRK · Merck & Co. — $324 billion
PFE · Pfizer — $140 billion
BMY · Bristol Myers Squibb — $127 billion
ZTS · Zoetis — $32 billion
VTRS · Viatris — $20 billion

← JMSB All stocks JOBY →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.